Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-3-10
pubmed:keyword
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/16,16-Dimethylprostaglandin E2, http://linkedlifedata.com/resource/pubmed/chemical/Abortifacient Agents, http://linkedlifedata.com/resource/pubmed/chemical/Alprostadil, http://linkedlifedata.com/resource/pubmed/chemical/Arbaprostil, http://linkedlifedata.com/resource/pubmed/chemical/Carboprost, http://linkedlifedata.com/resource/pubmed/chemical/Dinoprost, http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone, http://linkedlifedata.com/resource/pubmed/chemical/Hypertonic Solutions, http://linkedlifedata.com/resource/pubmed/chemical/Oxytocin, http://linkedlifedata.com/resource/pubmed/chemical/Progestins, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins E, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins E, Synthetic, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins F, http://linkedlifedata.com/resource/pubmed/chemical/Saline Solution, Hypertonic, http://linkedlifedata.com/resource/pubmed/chemical/Urea, http://linkedlifedata.com/resource/pubmed/chemical/gemeprost, http://linkedlifedata.com/resource/pubmed/chemical/meteneprost, http://linkedlifedata.com/resource/pubmed/chemical/sulprostone
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0015-0282
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5-17
pubmed:dateRevised
2006-11-15
pubmed:otherAbstract
PIP: This article outlines the current modalities of pregnancy termination, as well as their risks and complications, in 3 phases of pregnancy: 1) up to 49 days past the last menstrual period, 2) 8-15 weeks, and 3) 16-24 weeks. Before 8 weeks of pregnancy, suction dilatation and curettage (D and C) is the preferred method. However, a medical approach, possibly self-administered, is viewed as more satisfactory and requires only an improvement in side effects. From 8-15 weeks' gestation, suction D and C and dilatation and evacuation (D and E) are the methods of choice. The use of laminaria tents improves both the facility and safety of these procedures in nulliparous patients and perhaps in multiparous patients. Priming of the cervix with prostaglandin could further decrease the difficulty and risks of these procedures. The use of a hydrogel compound is especially worthy of consideration. There is controversy about the preferred method between 16-20 weeks' gestation. D and E appears to have fewer complications and to be more cost-effective than hypertonic saline injection. Urea-prostaglandin has fewer and less severe complications than saline injection, and seems to be more cost-effective than saline injection in terms of duration of hospitalization. The high frequency of failure and side effects, combined with the possibility of expulsion of a live fetus, make prostaglandin-only injection less desirable. After 20 weeks' gestation, urea-prostaglandin injection is probably the safer method. Given the rapid increase in complications with passing weeks, any delay in providing late abortion services should be avoided. 2nd trimester pregnancy terminations, especially those after 18 weeks' gestation, are associated with increased mortality and morbidity and should be performed at specialized centers where providers are better equipped to manage complications.
pubmed:meshHeading
pubmed-meshheading:3510916-16,16-Dimethylprostaglandin E2, pubmed-meshheading:3510916-Abortifacient Agents, pubmed-meshheading:3510916-Abortion, Induced, pubmed-meshheading:3510916-Alprostadil, pubmed-meshheading:3510916-Amnion, pubmed-meshheading:3510916-Anesthesia, pubmed-meshheading:3510916-Animals, pubmed-meshheading:3510916-Arbaprostil, pubmed-meshheading:3510916-Bacterial Infections, pubmed-meshheading:3510916-Carboprost, pubmed-meshheading:3510916-Cervix Uteri, pubmed-meshheading:3510916-Dilatation and Curettage, pubmed-meshheading:3510916-Dinoprost, pubmed-meshheading:3510916-Dinoprostone, pubmed-meshheading:3510916-Female, pubmed-meshheading:3510916-Humans, pubmed-meshheading:3510916-Hypertonic Solutions, pubmed-meshheading:3510916-Oxytocin, pubmed-meshheading:3510916-Pregnancy, pubmed-meshheading:3510916-Pregnancy Trimester, First, pubmed-meshheading:3510916-Pregnancy Trimester, Second, pubmed-meshheading:3510916-Progestins, pubmed-meshheading:3510916-Prostaglandins E, pubmed-meshheading:3510916-Prostaglandins E, Synthetic, pubmed-meshheading:3510916-Prostaglandins F, pubmed-meshheading:3510916-Pulmonary Embolism, pubmed-meshheading:3510916-Risk, pubmed-meshheading:3510916-Saline Solution, Hypertonic, pubmed-meshheading:3510916-Time Factors, pubmed-meshheading:3510916-Urea, pubmed-meshheading:3510916-Uterine Hemorrhage, pubmed-meshheading:3510916-Uterine Perforation
pubmed:year
1986
pubmed:articleTitle
Pregnancy termination: techniques, risks, and complications and their management.
pubmed:publicationType
Journal Article, Comparative Study, Review